Enfortumab vedotin (trade name Padcev) is a monoclonal antibody-drug conjugate used to treat adults with locally advanced or metastatic urinary tract cancer. It is used in combination with the chemotherapy drug, pembrolizumab. Enfortumab vedotin works by attaching to a protein in the cancer cells, allowing a chemotherapy drug to be delivered directly to the cancer cells and kill them.
Enfortumab vedotin, also sold under the brand name Padcev, is a medication used for treating a specific type of cancer. Here's a breakdown of its key points:
Type of drug: Enfortumab vedotin is an antibody-drug conjugate (ADC). This means it combines two components:
- Monoclonal antibody (enfortumab): This part targets a specific protein, nectin-4, which is found on some cancer cells.
- Cytotoxic drug (vedotin): This part is a cell-killing agent that disrupts cell division.
What it treats: Enfortumab vedotin is approved for the treatment of urothelial cancer, specifically locally advanced or metastatic urothelial cancer (la/mUC). Urothelial cancer is a type of cancer that forms in the lining of the urinary tract.
How it's given: Enfortumab vedotin is typically administered intravenously (through a vein) by a healthcare professional.
Used alone or in combination: Enfortumab vedotin can be used alone or in combination with another medication called pembrolizumab (an immunotherapy drug).
Important to note: I cannot provide any advice on the use of enfortumab vedotin or any other medication. If you have questions about this drug, it's important to consult with a licensed physician.